Author: admin

Tony Finelli MD, MSc, FRCSC GU Site Lead, Princess Margaret Cancer Center GU Lead, Cancer Care Ontario Associate Professor, University of Toronto presents Quality Indicators in Kidney Cancer Care at the Kidney Cancer Assoication meeting in Chicago 2014

Lara Barbara – Breast Cancer Survivor NSHOA Treats Patients with Chemo and Hugs brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Michael Murray – Primary Goal for Everyone at NSHOA is Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)         medical oncology, nshoa, the community oncology alliance (coa), coa, the coa patient advocacy network (cpan), cpan

Dr. Ron Burkes commenting on the results of the Lux-Lung8 Trial from ESMO 2014

Dr. Natasha Leighl, lead study author, on the newsiest results on the activity of pembrolizumab in lung cancer

Dr. Edith Perez speaking on the expanded results of the ALTTO breast cancer trial

Dr. Sunil Verma providing a comprehensive update on the latest lung cancer updates from ESMO 2014

Don Marx – Care for Today, Research for Tomorrow brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Dr. Tewari at ESMO 2014 on latest advanced cervical cancer therapies

Dr. Teresa Petrella and Dr. Catalin Mihalcioiu speaking on combination therapies in melanoma.

Mark Levine – CFO North Shore Hematology Oncology Focused on Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Immuno-Oncology: Shaping the Present, Transforming the Future and Raising the Bar in Oncology – from Best of ASCO Canada 2014

Nicole Gregory – The Chief Commercial Officer – What we do for our Patients brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Michael Mitrani – Guiding Patients Through the Benefits Maze brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Timothy A. Masterson, MD Assistant ProfessorDepartment of UrologyIndiana University Medical Center and Vitaly Margulis MD Associate Professor of Urology of UT Southern Medical Center debate the Debate: Partial Nephrectomy v. RADICALNephrectomy for T1b/2a tumors

Nicholas G. Cost, M.D.Assistant Professor, Department of Surgery, Division of Urology University of Colorado School of Medicine discusses Hereditary Syndromes in Kidney Cancer: Beyond VHL at the Kidney Cancer Association meeting in Chicago

Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine presents Management of Kidney Cancer in Young Patients at the Kidney Cancer Association meeting in Chicago

E. Jason Abel MD, FACS of the University of Wisconsin presents Renal mass biopsy for risk stratification in RCC: benefits and limitations at the Kidney Cancer Association meeting in Chicago.

Mark Purdue, PhDOntario Institute for Cancer Research discusses Epidemiology and Genomics of Renal Cell Carcinoma at the Kidney Cancer Association meeting in Chicago

Projecting Individual Probability for Developing Renal Cell Cancer presented by Xifeng Wu, MD, PHD, Professor and ChairDepartment of Epidemiology Betty B. Marcus Chair in Cancer Prevention Director, Center for Translational and Public Health Genomics at the annual Kidney Cancer Association meeting in 2014

At the iwNHL 2014, Dr Rafael Fonseca (Mayo Clinic, Arizona, USA) interviews Prof Keith Stewart (Mayo Clinic, Arizona, USA) and Prof Leif Bergsagel (Mayo Clinic, Arizona, USA), all doctors with an interest in myeloma, about the application of myeloma biology and therapies in lymphoma. Prof Stewart describes tumour heterogeneity and suggests a parallel between myeloma and indolent follicular lymphoma, where the presence of a more aggressive tumour subclone may have significant clinical implications. Prof Bergsagel describes the contribution of MYC to tumour heterogeneity and poor prognosis. Targeting the interaction between the immune system and tumour may provide new therapies.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, New York, USA) about the current and future clinical application of targeted or chemotherapy-free therapies in lymphoma. They discuss their experiences and some of the challenges of these therapies in clinical practice. It is emphasised that targeted therapies should not necessarily be used as standalone approaches. Combinations of targeted therapies and conventional therapies should be considered, and emerging clinical trials investigating combinations are described. The use of patient’s age to determine…

At the iwNHL 2014, Dr Steven Rosen (City of Hope National Medical Center, California, USA) describes the progress made in understanding the biology and management of non-Hodgkin lymphoma. Now, there is need to consider new drug combinations to maximise efficacy. Alternatives to chemotherapy including biologic approaches and future research directions including in precision medicine are examined.

At the iwNHL 2014, Dr Mathias Rummel (Justus-Liebig University-Hospital, Gießen, Germany) describes his research investigating the use of bendamustine plus rituximab in treating indolent and mantle-cell lymphomas, highlighting the clinical implications of his long-term findings. He also presents an overview of the progress in other treatment strategies. He concludes with a description of the current and prospective treatment strategies for indolent lymphomas.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. Understanding the biology of the lymphoma microenvironment may allow rational therapeutic targeting. Emerging clinical studies in this field are reviewed. The immune system is presented as a potential and attractive target to disrupt the interaction between the tumour and non-tumour microenvironment cells, with a focus on lenalidomide and rituximab immunotherapy.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. Improved trial designs, consideration of clinical variables and use of higher resolution approaches are recommended to overcome current research limitations in this field.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. The interaction between tumour cells and non-tumour cells has been increasingly recognised to contribute to disease progression.

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA), Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands), Prof Michael Pfreundschuh (University of Saarland, Homburg-Saar, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day two of the 12th iwNHL. The group discusses the value of a multidisciplinary approach in cancer management. Understanding of myeloma biology and therapies is proposed to be applicable to NHL; specifically, there is an emerging paradigm of tumour subclones that facilitate drug resistance. Implications of investigational lymphoma therapies are…

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada), Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day one of the 12th iwNHL. There is an increasing recognition of the lymphoma microenvironment in influencing tumour progression and clinical outcomes. In peripheral T-cell lymphomas, progress in understanding the interaction between tumour cells of origin and non-tumour cells may allow rational and novel therapeutic targeting. Future treatment options for patients with diffuse large B-cell lymphoma who…

At the iwNHL 2014, Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center, Pennsylvania, USA) and Prof Christian Gisselbrecht (Hôpital Saint-Louis, Paris, France) discuss the biology and management of diffuse large B-cell lymphoma (DLBCL). Dr Fisher describes the difficulties in defining and managing patients who are not cured by standard therapy. The classification of DLBCLs is an important consideration for research studies and clinical management. Double-hit lymphomas have poor prognosis and management options are discussed. Prof Gisselbrecht describes important recent advances in treatment options for different DLBCL subtypes. Future research directions and their…

At the iwNHL 2014, Prof Susan OBrien (MD Anderson Cancer Center, Texas, USA) and Prof Eva Kimby (Karolinska Institutet, Huddinge, Sweden) provide an overview of mantle cell lymphoma. Current treatment strategies are discussed. There is a focus on ibrutinib therapy for patients who relapse after first-line therapy and a comparison is made with its use in treating chronic lymphocytic leukaemia. Future trial and clinical directions are also examined.

At ESMO 2014, Dr Jennifer Temel is interviewed about the results of a phase III trial investigating the use of anamorelin in NSCLC patients with anorexia and cachexia. She discusses the next steps for anamorelin with a focus on regulatory approval and impact in clinical practice.

At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation of gefitinib with chemotherapy versus chemotherapy alone provided no significant improvement in progression-free survival in patients with EGFR mutation-positive lung cancer who previously failed to respond to first-line gefitinib.

At ESMO 2014, Prof Sandra Swain presents the results of the CLEOPATRA trial. This phase III trial in patients with HER2-positive metastatic breast cancer showed that treatment with pertuzumab combined with trastuzumab plus docetaxel (pertuzumab group) significantly improved overall survival versus placebo combined with trastuzumab plus docetaxel treatment (control group). Median overall survival in the pertuzumab group was increased by 15.7 months versus the control group.

During a press conference at ESMO 2014, Prof Frédéric Amant, University of Leuven, Leuven, Belgium, discusses his study on the impacts of mental and cardiac development in children who are exposed to chemotherapy or radiotherapy while in the womb.

At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed that MAGE-A3 cancer immunotherapy did not increase disease-free survival in patients with resected NSCLC.

During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of a Phase III study looking at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer after failure of platinum-based chemotherapy.

During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre Rosebank, Johannesburg, South Africa, presents the results of a Phase III study on the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

During the Saturday press conference at ESMO 2014, Professor David Currow describes results of Phase III data showing that a new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer, who are suffering cancer anorexia and cachexia. In the ROMANA studies, patients with unresectable stage III or IV non-small cell lung cancer with cachexia were randomized to receive either 100 mg anamorelin or placebo, given orally each day for 12 weeks. For those patients taking anamorelin, lean body mass and body weight were significantly increased. Professor Currow mentions that patients did not experience improvements in their…

Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be reviewed, with emphasis on patient selection and neuropathy management. The webinar was delivered by Dr. Malcolm Moore, Program Head, Medical Oncology and Hematology, Director, McCain Centre for Pancreatic Cancer; Professor, Department of Medicine and Pharmacology, University of Toronto.

The objective of this webinar was to provide an overview of the available front-line therapeutic options for patients with metastatic pancreatic cancer and compare the relative effectiveness and potential side effect profiles of different chemotherapeutic regimens.

A study published online in the August 2014 edition of the Annals of Surgical Oncology shows that BluePrint (Agendia Inc) proves to be superior to conventional subtyping for analyzing breast cancer before surgery. [1] The study, which will also be published in the October print edition of the journal, is part of the ongoing Neoadjuvant Breast Registry Symphony Trial (NBRST, pronounced “N-breast”).[2][3] These finding may eventually change the way physicians evaluate and treat breast cancer. The researchers concluded that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use…

Tamoxifen (Soltamox/Nolvadex®; AstraZeneca), an antagonist of the estrogen receptor ? in ER?-positive breast cancer has been effective in most patients. The drug has been used for more than 40 years to treat breast cancers that are hormone-receptor positive. As an adjuvant therapy tamoxifen improves overall survival. Its widespread use is thought to have made a significant contribution to the reduction in breast cancer mortality seen over the last decade. [1] However, resistance to tamoxifen is a clinically significant problem. So far, the mechanisms responsible for tamoxifen resistance remain elusive. Results from a study funded by the Dutch Cancer Society (KWF)…

The immune system has the ability to recognize tumors and to stop or control their development through a process known as immunosurveillance. The PD-1 checkpoint pathway plays a key role in modulating the immune system. This video describes how tumor cells exploit the PD-1 checkpoint pathway and evade the immune response, leading to tumor growth. Immuno-oncology

For more free video updates go to www.oncologyeducation.com Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not improve IDFS or OS in pts with high risk HER2- breast cancer. Bv did increase AEs but no unexpected AEs were encountered. Longer duration therapy is unlikely to be feasible given the high rate of early discontinuation due to all causes.

To view more free videos – visit www.oncologyeducation.com Profiling of protein expression, gene copy variations and mutations identified clinically relevant alterations in 99% of sarcomas. Given the overexpression of TOPO2 in approximately 50% of sarcomas, its utility as a biomarker of sensitivity to anthracyclines should be studied, especially in relation to TP53 status in a tumor. Trials of agents like mTOR and PI3K inhibitors could benefit from designs in which patient selection is based on PTEN loss or PIK3CA mutations instead of sarcoma histology. The prognostic implications of the co-existence of TP53 mutations and PTEN loss in sarcomas is yet…

For additional free GI/Colorectal Cancer video updates, please go to www.oncologyeducation.com Chemo/CET and chemo/BV equivalent in OS in pts KRAS wt (codons 12 + 13) MCRC; either is appropriate in first line. Overall OS of 29 + mos and 8% long-term survivors confirms progress in MCRC. The preference for FOLFOX limits chemotherapy comparison. Expanded RAS and other molecular and clinical analyses may identify subsets of pts who get more or less benefit from specific regimens.

Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK) and Prof Paul Richardson (Harvard Medical School, Boston, USA) at Myeloma 2014 about the treatment of myeloma. They discuss the trends in therapy they expect to see in the next decade and provide a response to the definitions workshop.

Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), and Prof San Miguel (University Hospital, Salamanca, Spain) at Myeloma 2014 about the treatment of Myeloma. They discuss novel targets and the treatment of high risk disease, and immune based therapy, and provide new insights in drug sensitivity and resistance.

Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), Dr Leif L. Bergsagel (Mayo Clinic, Scottsdale, Arizona), and Prof Antonio Palumbo (University of Torina, Torina, Italy) at Myeloma 2014, about the treatment of myeloma. They discuss the clinical implications and strategies to overcome clonal heterogeneity, genomics and practice, early treatment, immune based therapy, and new insights in IMiD drug sensitivity and resistance.